Hepatocyte-stimulating factor III shares structural and functional identity with leukemia-inhibitory factor - PubMed (original) (raw)
. 1989 Aug 15;143(4):1163-7.
Affiliations
- PMID: 2473120
Hepatocyte-stimulating factor III shares structural and functional identity with leukemia-inhibitory factor
H Baumann et al. J Immunol. 1989.
Abstract
The coordinate increase in the hepatic production of the acute phase plasma proteins appears to be mediated by several cytokines produced by different cell types. One factor, hepatocyte-stimulating factor III (HSF-III), constitutively produced by human squamous carcinoma (COLO-16) cells, stimulates the synthesis of the same set of acute phase plasma proteins as the structurally distinct IL-6. The physicochemical properties of HSF-III coincide with those of the T cell-derived leukemia-inhibitory factor (LIF). Human rLIF, tested on hepatoma cells, indicated a liver-regulating activity identical to HSF-III. The LIF activity is specifically neutralized by HSF-III antibodies. COLO-16 cells contain an LIF mRNA which is characteristic for lectin-stimulated T cells, suggesting that HSF-III is an epidermal cell-derived form of LIF. This result provides additional evidence for the close relationship between acute phase regulation of the liver and control of proliferation and differentiation of hemopoietic cells by identical cytokines.
Similar articles
- Are LIF and related cytokines functionally equivalent?
Piquet-Pellorce C, Grey L, Mereau A, Heath JK. Piquet-Pellorce C, et al. Exp Cell Res. 1994 Aug;213(2):340-7. doi: 10.1006/excr.1994.1208. Exp Cell Res. 1994. PMID: 8050491 - Effects of interleukin-6 and leukemia inhibitory factor on the acute phase response and DNA synthesis in cultured rat hepatocytes.
Kordula T, Rokita H, Koj A, Fiers W, Gauldie J, Baumann H. Kordula T, et al. Lymphokine Cytokine Res. 1991 Apr;10(1-2):23-6. Lymphokine Cytokine Res. 1991. PMID: 1714773 - The action of interleukin 6 and leukaemia inhibitory factor on liver cells.
Baumann H, Marinkovic-Pajovic S, Won KA, Jones VE, Campos SP, Jahreis GP, Morella KK. Baumann H, et al. Ciba Found Symp. 1992;167:100-14; discussion 114-24. doi: 10.1002/9780470514269.ch7. Ciba Found Symp. 1992. PMID: 1425008 Review.
Cited by
- Interleukin-6- and leukemia inhibitory factor-induced terminal differentiation of myeloid leukemia cells is blocked at an intermediate stage by constitutive c-myc.
Hoffman-Liebermann B, Liebermann DA. Hoffman-Liebermann B, et al. Mol Cell Biol. 1991 May;11(5):2375-81. doi: 10.1128/mcb.11.5.2375-2381.1991. Mol Cell Biol. 1991. PMID: 1901940 Free PMC article. - The paradigm of IL-6: from basic science to medicine.
Naka T, Nishimoto N, Kishimoto T. Naka T, et al. Arthritis Res. 2002;4 Suppl 3(Suppl 3):S233-42. doi: 10.1186/ar565. Epub 2002 May 9. Arthritis Res. 2002. PMID: 12110143 Free PMC article. Review. - The two C/EBP isoforms, IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 beta, are induced by IL-6 to promote acute phase gene transcription via different mechanisms.
Ramji DP, Vitelli A, Tronche F, Cortese R, Ciliberto G. Ramji DP, et al. Nucleic Acids Res. 1993 Jan 25;21(2):289-94. doi: 10.1093/nar/21.2.289. Nucleic Acids Res. 1993. PMID: 7680115 Free PMC article. - IL-1 receptor antagonist (IL-1Ra) does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumour cells.
Gabay C, Genin B, Mentha G, Iynedjian PB, Roux-Lombard P, Guerne PA. Gabay C, et al. Clin Exp Immunol. 1995 May;100(2):306-13. doi: 10.1111/j.1365-2249.1995.tb03669.x. Clin Exp Immunol. 1995. PMID: 7743670 Free PMC article. - Cloning, expression, and functional characterization of in-house prepared human leukemia inhibitory factor.
Rassouli H, Nemati S, Rezaeiani S, Sayadmanesh A, Gharaati MR, Salekdeh GH, Baharvand H, Gourabi H. Rassouli H, et al. Cell J. 2013 Summer;15(2):190-7. Epub 2013 Jul 2. Cell J. 2013. PMID: 23862122 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical